-
Je něco špatně v tomto záznamu ?
Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation
M. van Gelder, LC. de Wreede, M. Bornhäuser, D. Niederwieser, M. Karas, NS. Anderson, M. Gramatzki, P. Dreger, M. Michallet, E. Petersen, D. Bunjes, M. Potter, D. Beelen, JJ. Cornelissen, I. Yakoub-Agha, NH. Russell, J. Finke, H. Schoemans, A....
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Odkazy
PubMed
27941763
DOI
10.1038/bmt.2016.282
Knihovny.cz E-zdroje
- MeSH
- alografty MeSH
- časové faktory MeSH
- chronická lymfatická leukemie mortalita terapie MeSH
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mladiství MeSH
- následné studie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- senioři MeSH
- společnosti lékařské MeSH
- transplantace hematopoetických kmenových buněk * MeSH
- věkové faktory MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.
BMT Unit Department of Hematology Rigshospitalet Copenhagen Denmark
Bone Marrow Transplantation Center University Hospital Eppendorf Hamburg Germany
Center Hospitalier Lyon Sud Hématologie Lyon France
Department D'Hematologie CHU Nantes Nantes France
Department of Bone Marrow Transplantation University Hospital Essen Germany
Department of Haematology University Medical Center Utrecht The Netherlands
Department of Hematology Oncology Charles University Hospital Pilsen Czech Republic
Department of Hematology University Hospital Gasthuisberg Leuven Belgium
Department of Internal Medicine Hematology University Hospital Maastricht Maastricht The Netherlands
Department of Medicine Hematology Oncology University of Freiburg Freiburg Germany
Division of Hematology Oncology and Hemostasiology University Hospital Leipzig Leipzig Germany
Erasmus MC Daniel den Hoed Cancer Center Rotterdam The Netherlands
Hôpital HURIEZ UAM allo CSH CHRU Lille France
Hospital Clinic Institute of Hematology and Oncology Department of Hematology Barcelona Spain
Institute of Hematology and Blood Transfusion Prague Czech Republic
Klinik fuer Innere Medizin 3 Universitätsklinikum Ulm Ulm Germany
Leukaemia Myeloma Units Royal Marsden Hospital London Surrey UK
Medizinische Klinik und Poliklinik 5 University of Heidelberg Heidelberg Germany
Nottingham City Hospital Nottingham UK
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18016873
- 003
- CZ-PrNML
- 005
- 20180515103433.0
- 007
- ta
- 008
- 180515s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/bmt.2016.282 $2 doi
- 035 __
- $a (PubMed)27941763
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a van Gelder, M $u Department of Internal Medicine/Hematology, University Hospital Maastricht, Maastricht, The Netherlands.
- 245 10
- $a Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation / $c M. van Gelder, LC. de Wreede, M. Bornhäuser, D. Niederwieser, M. Karas, NS. Anderson, M. Gramatzki, P. Dreger, M. Michallet, E. Petersen, D. Bunjes, M. Potter, D. Beelen, JJ. Cornelissen, I. Yakoub-Agha, NH. Russell, J. Finke, H. Schoemans, A. Vitek, Á. Urbano-Ispízua, D. Blaise, L. Volin, P. Chevallier, D. Caballero, H. Putter, A. van Biezen, A. Henseler, S. Schönland, N. Kröger, J. Schetelig,
- 520 9_
- $a Even with the availability of targeted drugs, allogeneic hematopoietic cell transplantation (allo-HCT) is the only therapy with curative potential for patients with CLL. Cure can be assessed by comparing long-term survival of patients to the matched general population. Using data from 2589 patients who received allo-HCT between 2000 and 2010, we used landmark analyses and methods from relative survival analysis to calculate excess mortality compared with an age-, sex- and calendar year-matched general population. Estimated event-free survival, overall survival and non-relapse mortality (NRM) 10 years after allo-HCT were 28% (95% confidence interval (CI), 25-31), 35% (95% CI, 32-38) and 40% (95% CI, 37-42), respectively. Patients who passed the 5-year landmark event-free survival (N=394) had a 79% probability (95% CI, 73-85) of surviving the subsequent 5 years without an event. Relapse and NRM contributed equally to treatment failure. Five-year mortality for 45- and 65-year-old reference patients who were event-free at the 5-year landmark was 8% and 47% compared with 3% and 14% in the matched general population, respectively. The prospect of long-term disease-free survival remains an argument to consider allo-HCT for young patients with high-risk CLL, and programs to understand and prevent late causes of failure for long-term survivors are warranted, especially for older patients.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a alografty $7 D064591
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a přežití po terapii bez příznaků nemoci $7 D018572
- 650 _2
- $a Evropa $x epidemiologie $7 D005060
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x mortalita $x terapie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a de Wreede, L C $u DKMS, gemeinnützige GmbH, Tübingen, Germany. Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Bornhäuser, M $u Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden, Technische Universität Dresden, Dresden, Germany.
- 700 1_
- $a Niederwieser, D $u Division of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany.
- 700 1_
- $a Karas, M $u Department of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic.
- 700 1_
- $a Anderson, N S $u BMT Unit, Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
- 700 1_
- $a Gramatzki, M $u Division of Stem Cell Transplantation and Immunotherapy, University Hospital Schleswig-Holstein, Kiel, Germany.
- 700 1_
- $a Dreger, P $u Medizinische Klinik und Poliklinik V, University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Michallet, M $u Center Hospitalier Lyon-Sud - Hématologie, Lyon, France.
- 700 1_
- $a Petersen, E $u Department of Haematology, University Medical Center, Utrecht, The Netherlands.
- 700 1_
- $a Bunjes, D $u Klinik fuer Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany.
- 700 1_
- $a Potter, M $u Leukaemia Myeloma Units, Royal Marsden Hospital, London, Surrey, UK.
- 700 1_
- $a Beelen, D $u Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
- 700 1_
- $a Cornelissen, J J $u Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
- 700 1_
- $a Yakoub-Agha, I $u Hôpital HURIEZ, UAM allo-CSH, CHRU, Lille, France.
- 700 1_
- $a Russell, N H $u Nottingham City Hospital, Nottingham, UK.
- 700 1_
- $a Finke, J $u Department of Medicine-Hematology, Oncology, University of Freiburg, Freiburg, Germany.
- 700 1_
- $a Schoemans, H $u Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
- 700 1_
- $a Vitek, A $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Urbano-Ispízua, Á $u Hospital Clinic, Institute of Hematology and Oncology, Department of Hematology, Barcelona, Spain.
- 700 1_
- $a Blaise, D $u Programme de Transplantation and Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
- 700 1_
- $a Volin, L $u Stem Cell Transplantation Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
- 700 1_
- $a Chevallier, P $u Department D'Hematologie, CHU Nantes, Nantes, France.
- 700 1_
- $a Caballero, D $u Servicio de Hematología, Hospital Clínico, Salamanca, Spain.
- 700 1_
- $a Putter, H $u Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a van Biezen, A $u Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Henseler, A $u Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
- 700 1_
- $a Schönland, S $u Medizinische Klinik und Poliklinik V, University of Heidelberg, Heidelberg, Germany.
- 700 1_
- $a Kröger, N $u Bone Marrow Transplantation Center, University Hospital Eppendorf, Hamburg, Germany.
- 700 1_
- $a Schetelig, J $u DKMS, gemeinnützige GmbH, Tübingen, Germany. Medizinische Klinik und Poliklinik I, Universitätsklinikum Dresden, Technische Universität Dresden, Dresden, Germany.
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 52, č. 3 (2017), s. 372-380
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27941763 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20180515103607 $b ABA008
- 999 __
- $a ok $b bmc $g 1300497 $s 1013713
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 52 $c 3 $d 372-380 $e 20161212 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20180515
